SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950135-05-000276
Filing Date
2005-01-25
Accepted
2005-01-25 17:18:09
Documents
4
Period of Report
2005-01-25
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 ANTIGENICS INC. b532188ke8vk.htm 8-K 17287
2 EX-4.1 INDENTURE, DATED JANUARY 25, 2005 b532188kexv4w1.txt EX-4.1 301451
3 EX-4.2 REGISTRATION RIGHTS AGREEMENT, DATED JANUARY 25, 2005 b532188kexv4w2.txt EX-4.2 99231
4 EX-99.1 PRESS RELEASE DATED JANUARY 20, 2005 b532188kexv99w1.txt EX-99.1 3859
  Complete submission text file 0000950135-05-000276.txt   424126
Mailing Address 630 FIFTH AVENUE SUITE 2170 NEW YORK NY 10111
Business Address 630 FIFTH AVENUE SUITE 2170 NEW YORK NY 10111 2123324774
ANTIGENICS INC /DE/ (Filer) CIK: 0001098972 (see all company filings)

IRS No.: 061562417 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-29089 | Film No.: 05547785
SIC: 2836 Biological Products, (No Diagnostic Substances)